Keep in mind that the lack of rigor in the current pre-peer review literature coming out means that you have to take everything into account and with a grain of salt. For example, a drug showing effectiveness might have been with a mild case that started with a low viral load and wouldn’t have progressed any way (this is just an example, I’m not saying that is the case). Since the therapeutic index is so low, you can’t just dial up the dosage to treat severe cases that actually require pharmaceutical intervention, because it’s a non-starter.
